Form 4: Perspective Therapeutics CEO Johan Spoor Increases Stake in Company

CEO Johan Spoor recently purchased additional shares of Perspective Therapeutics, increasing his direct and indirect holdings in the company.

Summary

• Johan M. Spoor, CEO of Perspective Therapeutics, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• On March 28, 2025, Spoor purchased 22,026 shares of common stock at a weighted average price of $2.2421, with prices ranging from $2.1900 to $2.3000.
• He also purchased 4,650 shares at a weighted average price of $2.2125, with prices ranging from $2.1900 to $2.2450.
• Following these transactions, Spoor directly owns 59,383 shares.
• The filing also corrects previous reporting errors regarding the ownership of certain shares held by his spouse and children.
• Spoor indirectly owns shares through his IRA, his spouse's IRA, his spouse, and Uniform Transfers to Minors Act accounts for his two children.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While insider buying can be seen as positive, it's a routine transaction and the filing also includes corrections of past errors.

Positives

• The CEO's purchase of additional shares may signal confidence in the company's future prospects.
• The correction of previous reporting errors improves transparency and accuracy in ownership disclosures.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. Investors often monitor these filings for signals about management's confidence in the company's prospects.

Stakeholder Impact

• Shareholders may view the CEO's stock purchase as a positive signal.
• The correction of reporting errors ensures accurate information for all stakeholders.

Key Dates

Keywords

Form 4, beneficial ownership, stock purchase, Perspective Therapeutics, Johan Spoor, CATX